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The incidence of cervical cancer in Eastern European countries is high, however uptake of available prevention strategies is suboptimal.  We explored the knowledge, behaviours and attitudes towards cervical cancer prevention strategies in Latvian women.

Methods
A mixed-methods study of Latvian women, consisting of questionnaire surveys and semi-structured interviews, was conducted in Riga, Latvia between September-October 2015. 

Results
158 surveys were completed and 10 interviews were conducted. 87%(n=135) had previously had a smear test. 67%(n=105) correctly identified that cervical cytology was performed to identify pre-cancerous changes. The practice of annual gynaecological reviews was prevalent and many believed it to be synonymous with cervical screening. Detailed knowledge of HPV and the HPV vaccine was deficient, although 73%(n=115) and 70%(n=90) respectively claimed to have heard of them. Negative attitudes existed regarding the HPV vaccine due to fear of potential side effects. On learning that HPV was an sexually transmitted infection, the notion of testing positive for HPV was met with shame and embarrassment.   

Conclusions
A small proportion of Latvian women are over-screened whilst many women remain unscreened. The main contributing factor for this was their poor understanding of the roles cervical screening and HPV vaccination play in the prevention of cervical cancer. 
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1. INTRODUCTION
Cervical cancer (CC) related mortality is disproportionally higher in Eastern Europe (EE) than in Western Europe  ADDIN EN.CITE (, ). This gap is likely to widen as CC mortality in EE continues to increase (). The absence of national cervical screening (CS) programmes (CSP) has been reported as a significant contributing factor  ADDIN EN.CITE (, ), with countries that have established structured CSPs having demonstrated a reduction in mortality and incidence of CC (). 

In recent years the majority of EE countries have introduced CSPs, however they differ in their organisational infrastructures, for example the Czech republic offers CS annually, Estonia’s screen interval is 5 years and in Latvia it is 3 years  ADDIN EN.CITE (). Many programmes have low coverage of their target populations, ranging from 8% in Romania to 72% in Slovenia  ADDIN EN.CITE (), often due to out-of-programme opportunistic screening, and are not underpinned by robust quality assurance mechanisms  ADDIN EN.CITE (). Consequently, the impact of these CSPs appears limited with very little reduction in CC incidence or mortality rates.

Latvia harbours one of the highest CC incidence and mortality rates in Europe (). The incidence has increased substantially from 8.9/100,000 in 1989 () when screening was a mandatory component of annual health checks, to 25.1/100,000 in 2014 () following discontinuation of compulsory screening in 1989 and 20 years of opportunistic-only screening (). A fully-funded national CSP started in 2009, published data has reported screening coverage to reach a maximum of 59%, with 41% of these women accessing screening outside the national programme (). Equally, following the implementation of a state-funded HPV vaccination programme in Latvia (2010), uptake of the human papillomavirus (HPV) vaccine has been low (53.4% in 2012  ADDIN EN.CITE ()). 

Not all EE countries face the same issues when trying to encourage CS participation; however, there are commonalities as a result of their shared experiences during the Soviet era. Taking Latvia as representative of many EE countries, we have performed an in-depth analysis of the knowledge, behaviours and attitudes regarding CC prevention strategies in women to inform screening programmes and educational campaigns.

2. METHODS
Ethical approval was obtained from the University of Latvia ethics commission board (13/08/2015). 

A mixed-methods study of questionnaire surveys and one-to-one semi-structured qualitative interviews was conducted. Latvian women in Riga aged 20 and above, were eligible for the study. The age criterion was not based on the Latvian CSP recommendations (25-69 years), as many women are opportunistically screened outside the programme (). 

2.1 Questionnaire Study
The survey was developed following a literature search and pre-protocol patient and public involvement work (PPI). The 28-item survey explored existing screening behaviours, CC and CS knowledge and HPV and HPV vaccine awareness. Pre-validated questions  ADDIN EN.CITE () were incorporated into the survey. The overall face validity of the instrument was confirmed by peer review from experts within the speciality and the PPI groups. The survey was developed in English and translated into Latvian by the Latvian researchers. 
A purposive sampling approach was adopted, between September and October 2015, to recruit patients from a state-funded General Practitioner (GP) surgery in Riga and colposcopy clinics at Riga East Clinical University Hospital. The women completed the anonymous survey prior to their consultations. The data were transferred into the Statistical Package for Social Sciences, IL, USA, version 22. Descriptive statistics were generated for the responses and Chi square test or Fisher exact test, were used for analysis. P-values were assessed using two-sided tests and statistical significance was taken as a cut-off of p≤0.05.

2.2 Semi-Structured Interviews
Participants self-volunteered at the end of the survey to be interviewed. The objective of the interviews was to obtain detailed understanding of screening behaviours, access to healthcare in Latvia and issues surrounding HPV testing and vaccination. HP (first author) conducted the interviews in English and an interpreter was offered to the participants. 




In total 158/200 surveys were completed, 25 from primary care and 133 from secondary care; overall response rate of 79%. Detailed demographics are presented in Table 1.

Most women (67%, n=105) understood the smear test is a screening tool to identify pre-cancerous cervical changes, which lacks diagnostic ability (72%, n=113) (Table 2). Around half (53%, n=83) selected only the true options for the question “Why are cervical smear tests performed?” 

Most women had heard of HPV (73%, n=115/157) but demonstrated limited knowledge of HPV (Table 3). In those women who had either heard of HPV or were not sure if they had (10%, n=16), median scores for general HPV knowledge and HPV testing questions, were 7/15 (range 0-15) and 4/6 (range 0-6) respectively. Fewer women responded to the questions about the HPV vaccine, 70% (n=90/129) had heard of the HPV vaccine and only 4% (n=5) had received it. 

Younger age was significantly correlated with general HPV knowledge (-0.28 [Spearman’s rho correlation coefficient]: p=< 0.01),) and HPV vaccine knowledge (- 0.21[Spearman’s rho correlation coefficient]: p=0.01). Higher educational attainment was associated with higher HPV testing knowledge score (0.19[Spearman’s rho correlation coefficient]: p=0.02). Neither marital nor employment status showed any significant correlations.

3.2 Semi-structured interviews
Ten interviews were conducted; five women from primary care and five from secondary care. Their median age was 35 years (range 20-62 years). Details in parentheses following quotes represent the participant's identification number (P) and age (in years).  
* Quote via interpreter.

Doctor-patient relationship
It was apparent that there was considerable trust vested in doctors, their advice was not to be questioned nor was it felt necessary to conduct independent research. The women were willing to alter health behaviours (e.g. frequency of CS) based purely on the recommendation of the doctor. 

“So if the doctor says that you need to do this, she will do that. She is not one of those people who spend hours researching the internet, yes” *(P8,43)

Annual gynaecological reviews
The practice of “annual gynaecological reviews” was prevalent and appeared to have been passed down generations and was accepted as the norm. Reproductive organs were seen to be more valuable than other organs, whereby they needed to be protected and hence the need for prophylactic screening. 

“…but I know from the childhood, from teenagers, that you have to go to gynaecologist at least every year to check everything” (P4,34)

Despite obvious concern regarding their reproductive organs the women had little understanding of the examinations/investigations that were performed during their annual review. The gynaecologist was responsible for determining which tests were required, “..she comes and the Gynaecologist does A, B and C” *(P9,37).

Cervical screening behaviours- Motivators
Most women attended CS annually with some going as frequently as 3-6 months. They described a feeling of “fear” that something would be missed if they waited the recommended three years and having annual smears made them feel “safe”. The reason for the national CSP not recommending more frequent screening was believed to be financially motivated.

“I think it’s just connected with [-] the Government money, but I think every woman should go at least one a year by her own means” (P5,35)

The practice of annual smears/checks up appeared to be imbedded in the women’s culture and the gynaecologist further reinforced it. Their motives for screening, included the gynaecologist recommended it, “just as usual” (P3,62), “I think you have to do this”(P4,34) and “because I was pregnant and it’s normal to know about my health..”(P5,35).  It wasn’t clear if they fully appreciated that CS was different to the annual gynaecological check.

Cervical screening behaviours- Barriers
Perceived barriers to screening included that many women may not have heard of CS so they just ignore the invitation letters. Access was an issue, particularly for women who resided in remote villages. Time played a role in two ways; the length of time that one would have to wait to get an appointment and the women were generally too busy to make time. Lastly because they were asymptomatic screening was not prioritised.

Knowledge and understanding of cervical screening, cervical cancer and HPV
Cervical screening
Many of the women were aware of the national CSP in Latvia, mainly from receiving the smear invitation letter. Most women were able to provide an accurate description of what a smear test involved and its purpose, however others were less clear and believed that it was testing for “some kind of fungus or stuff like that”(P1,20).

Knowledge regarding the management of an abnormal smear was poor, with an assumption that further examination was required but no knowledge of what form this might take. There was a lack of awareness of the consequences of multiple treatments.

Cervical cancer
The scale of the disease burden in Latvia was underestimated; “…nobody has heard about cancer of cervix..” (P1, 20)
Risk factors for developing CC were stated as multiple partners, hereditary, lifestyle, multiparity and a connection to uterine fibroids. The causal relationship between HPV and the development of CC was acknowledged but not the strength/seriousness of the association.

HPV
Many had heard of HPV but detailed knowledge was variable. The prevalence of HPV in Latvian women was underestimated. Some women correctly identified that HPV was sexually transmitted whereas others were not sure how it was transmitted.
The women claimed to have heard of the HPV vaccine when prompted but had limited knowledge.

 “She does know that the vaccine is intended to prevent cervical cancer, but she does not know the connection between the vaccine and HPV” *(P8,43).

Beliefs, perceptions and attitudes towards the Human Papillomavirus
Latvia was described as a religious country and therefore the women believed that HPV would not be spoken of openly, stemming from the misconception that HPV infection is synonymous with sexual promiscuity.

“Latvians are quite religious so they don’t like to talk about, especially like when the person is changing partners quite often…”  (P10,30)

Negative views were expressed towards the HPV vaccine since it was felt that the available scientific information was inadequate. HPV was felt to be a relatively new concern, “30 years ago we didn’t hear about this problem” (P4,34). Fear of the side effects of such a new vaccine was reported as a major barrier to vaccine acceptance.

Emotions
“Scared” and “shame” were the most frequently quoted emotions. Participants were “scared of the unknown” (P1,20),  “scared because [-] they will discover something”(P10,30) and “afraid of cancer in case if it will develop within three years”(P3,62). Afraid that something maybe missed or of starting a new relationship in the fear that they may contract the virus again.
‘Shame’ was used alongside the potential of discussing sexual behaviours with parents or healthcare professionals.

“not everybody talks about it and in different cultures it’s like a shame to talk about it” (P10,30).

4. DISCUSSION
This mixed-methods study highlights complex interactions that exist between knowledge, self perceived health and importance of health that govern CC prevention uptake.  There was a lack of awareness of the high incidence of CC in Latvia, resulting in poor self-perceived susceptibility, as well as an ingrained cultural practice of annual gynaecology reviews and a mistrust of the government-funded programmes.

Attendance for screening in this cohort was higher (87%) than the national screening coverage of 59% (), which is consistent with the majority of participants for the survey being recruited from colposcopy clinics. Worryingly, 14% (19/130) of the women recruited from colposcopy clinics claimed they had not previously had a smear test. It was unclear if all the interviewed women appreciated the difference between annual gynaecological reviews and CS. An Estonian study found that a recent visit to the gynaecologist was the most commonly stated reason for non-attendance to CS (). Attending screening opportunistically was prevalent in this cohort. One pitfall of opportunistic screening is the performance of unnecessary diagnostic procedures and treatments (). Pelvic examinations have been described by women as causing discomfort and embarrassment (); a bad experience with an unnecessary pelvic examination may jeopardise future participation with CS  ADDIN EN.CITE (). The practice of “gynaecological screening” is also prevalent in other EE countries  ADDIN EN.CITE (, ), which might explain the low uptake of national CS in Eastern Europe   ADDIN EN.CITE (, ). 
Overall there was good awareness of the Latvian national CSP and therefore lack of compliance would suggest there is an issue with acceptability and/or communication about the justification of the recommended practice. Healthcare professionals may also find the national programme problematic, as some women quoted “gynaecologist recommendation” as a reason for opportunistic CS. This study showed that there was a great amount of trust bestowed in the advice of the doctor and therefore one could argue that to increase participation with national CS the focus should be on changing the attitudes of healthcare professionals.   

The survey and interviews revealed that detailed HPV and HPV vaccine knowledge was poor amongst Latvian women; although HPV testing is not routinely part of the CSP in Latvia  ADDIN EN.CITE (), the HPV vaccine has been available since 2010 (). Concerns regarding HPV vaccine side effects and that the vaccine is “new/experimental”, have also been found in Romanian mothers where there is low vaccine uptake   ADDIN EN.CITE (), despite the HPV vaccine not being found to be associated with any serious adverse effects  ().  Mothers’ own participation with preventative healthcare has been shown to be associated with enhanced engagement of daughters with screening and vaccination (). In our cohort it was evident that women had a heightened sense of protection for their reproductive organs but did not fully appreciate the benefits of primary prevention. Therefore, only the practice “annual gynaecological reviews” was being passed down the generations.

Overall there was poor knowledge about cervical cancer and its natural history. Lack of knowledge and awareness has been associated with poor screening attendance  ADDIN EN.CITE (). Poor knowledge levels can result in lower self-perceived susceptibility. It is difficult to accurately assess the CS behaviours of the women in this study, as many were not clear about the difference between their routine gynaecological review and CS. It is possible that they had a smear test performed at each of their reviews or alternatively that they never had a smear test performed.  The opportunistic screening described was performed in the private sector, therefore no databases exist and implementing any quality assurance is difficult.   

Participation with organized cervical screening that has good quality assurance can be increased through greater patient engagement. To achieve this awareness of cervical cancer needs to be increased and the use of media outlets provides one possible method of accomplishing this. In addition, healthcare professionals have a vital role to play in patient education and in endorsing participation with the national cervical screening programme. 

4.1 Limitations
Participants were recruited from a single GP practice and single hospital institute, which could result in facility bias and may not be representative of the general population. The interview participants might represent a group who are inherently more likely to engage with screening, as they self-volunteered to partake in the study. Targeting women who do not attend for screening is very challenging and it is just as important to look at what motivates women to attend for screening as it to explore the barriers to screening in non-attenders   ADDIN EN.CITE ().

5. CONCLUSIONS
The current cervical screening behaviours in Latvian women appear to be governed by their lack of knowledge of the principles of screening and the natural history of the development of cervical cancer. The results could be extrapolated to many EE countries that share a common Soviet heritage with Latvia, and give clinicians and policy makers insights into the misconceptions that need to be overcome to achieve greater patient engagement with cervical cancer prevention initiatives.
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Table 1 Socio-demographic characteristics
	n=158
Age (median/range)	36 (21-71)




	In a civil partnership	17 (11)
	In a relationship	18 (11)
	Co-habiting	18 (11)
	Single	6 (4)
Education n(%)	No formal Qualifications	2 (1)
	Trade/technical /vocational	38 (24)
	GCSE’s/O Levels or equivalent	29 (18)
	A Level or equivalent	7 (4)
	First degree	49 (31)
	Post Graduate degree	28 (18)
	Other	5 (3)
Employment Status n(%)	Employed full time	114 (72)














Table 2 Cervical screening behaviours and knowledge

	n (%)
Why are cervical smears tests preformed? (select all true options) (n= 157)	Diagnose pre-cancerous cervical cells	Correct	105 (67)
		Incorrect	52 (33)
	Diagnose cervical cancer	Correct	113 (72)
		Incorrect	44 (28)
	Pick up STD’s	Correct	151 (96)
		Incorrect	6 (4)
	As part of a full gynaecological examination	Correct	121(77)
		Incorrect	36 (23)
Aware of free cervical screening in Latvia(n=155)	Yes	135 (87)
	No	20 (13)
Source of information about smear tests(n=135)	GP	26 (19)
	Friends	2 (1)
	Smear invitation letter	87 (64)
	Other	24 (18)
What is the recommended screening commencement age in Latvia? (median/range) (n=117)	25 (15- 50)
Recommended screen frequency in Latvia(n=139)	Don’t know	1 (1)
	Every 6 months	10 (7)
	Every year	46 (33)
	Every 3 years	82 (59)
Have you ever had a smear test?(n=155)	Yes	135 (87)
	No	16 (10)
	Not sure	4 (3)
Age of first smear test (median/range)(n=121)	25 (18-55)
Country of first smear test (n=128)	Latvia	122 (95)
	Other 	3 (2)
	Not sure	3 (2)
Timing of most recent smear test (n=149)	Never had one	15 (10)
	0-3 years	124 (83)
	4-5 years 	8 (5)
	More than 5 years 	2 (1)





Table 3 HPV and HPV vaccine knowledge 

	Correct ResponseN (%)	IncorrectResponseN (%)
General HPV knowledge questions (n=116)*
HPV is very rare	110 (95)	6 (5)
HPV always has visible signs or symptoms	107 (92)	9 (8)
HPV can cause cervical cancer	88 (76)	28 (24)
HPV can be passed on by genital skin-to-skin contact	27 (23)	89 (77)
There are many types of HPV	54 (47)	62 (53)
HPV can be passed on during sexual intercourse	59 (51)	57 (49)
HPV can cause genital warts	26 (22)	90 (78)
Men cannot get HPV	107 (92)	9 (8)
Using condoms reduces the risk of getting HPV	47 (41)	69 (59)
HPV can be cured with antibiotics	105 (90)	11 (10)
Having many sexual partners increases the risk of getting HPV	55 (47)	61 (53)
HPV usually doesn’t need any treatment	7 (6)	109 (93)
Most sexually active people will get HPV at some point in their lives	24 (21)	92 (79)
A person could have HPV for many years without knowing it	59 (51)	57 (49)
Having sex at an early age increases the risk of getting HPV	32 (28)	84 (72)

HPV testing knowledge questions (n=91)
An HPV test can tell how long you have had an HPV infection	82 (90)	9 (10)
If a woman tests positive for HPV she will definitely get cervical cancer	85 (93)	6 (7)
An HPV test can be done at the same time as a Smear test	58 (64)	33 (36)
HPV testing is used to indicate if the HPV vaccine is needed	73 (79)	18 (20)
When you have an HPV test, you get the results the same day	80 (88)	11 (12)
If an HPV test shows that a woman does not have HPV her risk of cervical cancer is low	41 (45)	50 (55)

HPV vaccine knowledge questions (n=80)
HPV vaccines require two doses	35 (44)	45 (56)
The HPV vaccines offer protection against all sexually transmitted infections	78 (98)	2 (2)
The HPV vaccines are most effective if given to people who have never had sex	57 (71)	23 (29)
Someone who has had HPV vaccine cannot develop cervical cancer	70 (88)	10 (12)
The HPV vaccines offer protection against most cervical cancers	45 (56)	35 (44)
One of the HPV vaccines offers protection against genital warts	7 (9)	73 (91)
Girls who have had the HPV vaccine do not need to have smear tests when they are older	78 (98)	2 (2)
 
















